CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% Drug Patent Profile
✉ Email this page to a colleague
When do Clindamycin Phosphate In Dextrose 5% patents expire, and what generic alternatives are available?
Clindamycin Phosphate In Dextrose 5% is a drug marketed by Abraxis Pharm, Hikma, Abbott Labs, and Baxter Hlthcare. and is included in five NDAs.
The generic ingredient in CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% is clindamycin phosphate. There is one drug master file entry for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clindamycin Phosphate In Dextrose 5%
A generic version of CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% was approved as clindamycin phosphate by HIKMA on April 25th, 1988.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%?
- What are the global sales for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%?
- What is Average Wholesale Price for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%?
Summary for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 33 |
| Clinical Trials: | 33 |
| DailyMed Link: | CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% at DailyMed |
Recent Clinical Trials for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sun Pharmaceutical Industries, Inc. | PHASE1 |
| Ain Shams Maternity Hospital | NA |
| Shehab Ahmed Hamad | PHASE3 |
See all CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% clinical trials
Pharmacology for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
| Drug Class | Lincosamide Antibacterial |
| Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |

